Meeting
2023 ASCO Annual Meeting
DCK expression by RNAseq as a potential biomarker of gemcitabine response in sarcoma.
Authors
David A. Liebner
The Ohio State University, Columbus, OH
David A. Liebner , Erin A Fetzer , Marium Husain , James Lin Chen , Gabriel Tinoco
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 11578)
DOI
10.1200/JCO.2023.41.16_suppl.11578
Abstract #
11578
Poster Bd #
512
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Prevalence of ultra-rare undifferentiated round cells sarcoma of bone and soft tissue after genomic classification.
First Author: Emanuela Palmerini
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2020 ASCO Virtual Scientific Program
NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.
First Author: Matthew Ingham
Poster
2019 ASCO Annual Meeting
Activity of hormonal treatment in uterine smooth muscle tumors of uncertain malignant potential (STUMP): A mono-institutional referral center experience in advanced disease.
First Author: Roberta Sanfilippo